Verizon Communications (VZ) Tops Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Jefferies Reiterates Buy Following Verizon Communications (VZ) 3Q Results
October 21, 2015 9:04 AM EDTJefferies reiterated a Buy rating and $53.00 price target on Verizon Communications (NYSE: VZ) following the company's 3Q15 earnings results.
Analyst Mike McCormack commented, "Results reflected better profitability in both Wireless and Wireline. Wireless continues to perform well in a challenging environment, evident in... More
Cowen Reiterates Market Perform as Verizon Communications (VZ) Reports In-Line Results
October 21, 2015 6:55 AM EDTCowen reiterated a Market Perform rating and $48.00 price target on Verizon Communications (NYSE: VZ) following the company's 3Q15 earnings results. VZ reported mostly in line 3Q15 results including rev/EPS of $33.16B/$1.04 vs. the Streets $32.97B/$1.02E.
Analyst Colby Synesael commented, "VZ... More
Wall Street ends down with healthcare, IBM; United Tech rises
October 20, 2015 7:13 AM EDTBy Caroline Valetkevitch
(Reuters) - U.S. stocks ended slightly lower on Tuesday as a decline in healthcare and biotech stocks offset gains in United Technologies and Verizon.
A 5.7 percent drop to $140.64 in IBM (NYSE: IBM) also weighed on the market. The stock hit a five-year intraday low at $140.28 after it reported a bigger-than-expected decline in quarterly revenue and cut its full-year profit forecast.
The S&P healthcare sector fell 1.5 percent, while the Nasdaq Biotech Index dropped 3.2 percent. Concerns about drug pricing have hit biotech and other healthcare shares.
... More